Premium
Pdn‐21: Possible tumor marker for medullary thyroid carcinoma
Author(s) -
Takami Hiroshi,
Shikata JunIchi,
Horie Hitoshi,
Sekine Kyouichi,
Ito Kunihiko
Publication year - 1990
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930440403
Subject(s) - calcitonin , medicine , thyroid carcinoma , medullary carcinoma , medullary cavity , calcitonin gene related peptide , thyroid , tumor marker , carcinoma , pathology , oncology , endocrinology , cancer research , cancer , neuropeptide , receptor
Abstract The plasma level of PDN‐21 was measured by RIA in 10 patients with medullary thyroid carcinoma (MTC). All 10 patients with MTC had extremely elevated PDN‐21 levels. The correlations between PDN‐21, calcitonin gene‐related peptide, and calcitonin, (all of which are calcitonin gene products) were significant ( P < .001) in the 10 MTC patients. This study suggests that PDN‐21, as well as calcitonin, may be a useful marker for the detection of patients with MTC.